Daconib 45 mg (Dacomitinib) Tablets

Daconib 45 mg (Dacomitinib) is a targeted anticancer medicine used in the management of specific types of lung cancer. It is designed to block abnormal epidermal growth factor receptor (EGFR) signaling pathways that contribute to cancer cell growth and spread.

Therapeutic Effects

• Helps slow or stop the growth of cancer cells with EGFR mutations.
• Supports disease control in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
• May help reduce tumor progression and improve progression-free survival.
• Targets cancer cells more specifically than traditional chemotherapy.
• Assists in delaying disease advancement in eligible patients.
• Provides an oral treatment option for patients with EGFR mutation-positive lung cancer.

Primary Uses

• First-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion mutations.
• Treatment of metastatic NSCLC with EGFR exon 21 L858R substitution mutations.
• Management of advanced EGFR mutation-positive lung cancer as prescribed by an oncology specialist.

Active Ingredient

Dacomitinib INN – 45 mg

Composition

Each film-coated tablet contains:

• Dacomitinib 45 mg (as Dacomitinib hydrate)
• Pharmaceutical excipients q.s.

Pharmacological Category

• Epidermal Growth Factor Receptor (EGFR) Inhibitor
• Tyrosine Kinase Inhibitor (TKI)
• Targeted Anticancer Agent

Mechanism-Based Classification

Dacomitinib is an oral, irreversible EGFR tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in tumor cell proliferation, survival, and metastasis.

Recommended Adult Dose

45 mg orally once daily, or as directed by a qualified healthcare professional.

Administration Instructions

• Take the tablet at approximately the same time each day.
• Swallow whole with water.
• Do not crush, chew, or split the tablet.
• Can be taken with or without food.
• Continue treatment as prescribed unless advised otherwise by the treating physician.

Missed Dose

• If a dose is missed, skip the missed dose and take the next scheduled dose at the regular time.
• Do not take two doses at the same time to compensate for a missed dose.

Dose Adjustments

• Dose modifications may be required based on treatment-related adverse reactions.
• Temporary interruption, dose reduction, or discontinuation may be recommended by the healthcare provider depending on patient tolerance and clinical response.

Important Administration Considerations

• Treatment should be initiated only after confirmation of EGFR mutation status through an appropriate diagnostic test.
• Regular monitoring is recommended during therapy.
• Follow all instructions provided by the oncology care team for optimal treatment outcomes.

Always use Daconib 45 mg exactly as prescribed by your healthcare professional.